Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Biocept ($BIOC) stock showed strong movements as the company announced that its new liquid biopsy test for progesterone receptor (PR), a biomarker in the blood for breast cancer, is now commercially available. Veena Singh, M.D., Biocept's Senior Vice President and Medical Director said, “With the addition of PR detection using our high sensitivity CTC platform, we offers liquid biopsy assays for all NCCN Guideline®-based biomarkers pertinent to the care of patients with breast cancer." The company’s Target Selector™ PR expression test is performed on CTCs utilizing fluorescently labeled antibodies. It performs the liquid biopsy tests in its CLIA-certified, CAP-accredited laboratory located in San Diego, California.
The company stock has gained over 96 percent in this year so far while it lost 20 percent of its value in the past 12 months.

CTI BioPharma Corp. ($CTIC) reported that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval of pacritinib for the treatment of myelofibrosis patients who have thrombocytopenia (low blood platelets). With this validation, the centralized review process by the EMA's Committee for Medicinal Products for Human Use (CHMP). The 210 days long CHMP review period is succeeded by the European Commission review, which offers its final decision on EU authorization within three months. The authorization grants a marketing license valid in all 28 EU member states.
The company stock reacted positively to the news and gained over 4 percent in its Friday trading session.

 

Amgen ($AMGN) announced filing regulatory applications in the US and Europe seeking approval to add overall survival (OS) data to the label of multiple myeloma med KYPROLIS (carfilzomib). The Phase 3 ENDEAVOR study showed almost an eight-month survival benefit over Takeda's VELCADE (bortezomib).

Athenahealth ($ATHN) announced that its Chief Financial Officer Karl Stubelis, plans to step down after reporting Q2 results. Board member Jack Kane will take over on an interim basis until a permanent successor is hired.

Lannett Company ($LCI) announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for its generic version of Lyne Laboratories' Cyproheptadine Hydrochloride Syrup for the symptomatic treatment of allergic reactions.
Bristol Myers Squibb ($BMY) reported that the FDA has accepted its supplemental New Drug Application (sNDA) seeking approval of Sprycel for the treatment of children with Philadelphia chromosome-positive (Ph+) chronic phase chronic myeloid leukemia in addition to a powder for oral suspension formulation under priority review.

 

Emergent BioSolutions ($EBS) announced inking a new deal with Sanofi Pasteur Biologics, LLC and Acambis Research Ltd. to acquire the ACAM2000 business. The deal is estimated to be worth $97.5 million in upfront payment and up to $27.5 million in regulatory and other milestones.

Brokerage Action Company Rating Price Target Impact on Share Price Actions
Stifel Nicolaus Reiterates ABAXIS (ABAX)
Hold $48.00 N/A
Cowen and Company Reiterates Abbott Laboratories (ABT)
Outperform $48.00 -> $55.00 Low

Jefferies Group LLC Reiterates AcelRx Pharmaceuticals (ACRX)
Buy -> Buy $7.00 High

Piper Jaffray Companies Reiterates Allergan PLC. (AGN)
Hold $231.00 N/A
SunTrust Banks Reiterates Alexion Pharmaceuticals (ALXN)
Buy $165.00 Low

Oppenheimer Holdings Reiterates Amgen (AMGN)
Outperform $189.00 Low

Credit Suisse Group Reiterates Amgen (AMGN)
Hold $177.00 N/A

Gainers (% price change)Last TradeChangeMkt CapAcelRx PharmaceuticalsACRX2.40+0.25 (11.63%)104.07MBioDelivery Sciences IntlBDSI3.05+0.25 (8.93%)174.99MOmeros CorporationOMER21.32+1.34 (6.71%)941.03MSangamo Therapeutics IncSGMO10.10+0.60 (6.32%)848.02MAstraZeneca plc (ADR)AZN33.87+1.48 (4.57%)84.10BLosers (% price change)AVEO Pharmaceuticals, IncAVEO2.66-0.19 (-6.67%)289.50MInsys Therapeutics IncINSY12.15-0.64 (-5.00%)906.08MNewLink Genetics CorpNLNK7.38-0.35 (-4.53%)217.37MImmunoGen, Inc.IMGN6.79-0.31 (-4.37%)622.46MTeva PharmaceuticalTEVA31.90-1.29 (-3.89%)33.52BMost Actives (dollar volume)Johnson & JohnsonJNJ132.60+0.74 (0.56%)356.20BTeva PharmaceuticalTEVA31.90-1.29 (-3.89%)33.52BUnitedHealth Group IncUNH186.90+1.42 (0.77%)178.94BAmgen, Inc.AMGN177.13+2.09 (1.19%)131.59BCelgene CorporationCELG134.57+0.10 (0.07%)105.79B